Organon & Co.

Organisation

30 Hudson Street, Jersey City, NJ, United States, 07302

Headquarters

10000

Employees

Healthcare

Industry

Kevin Ali

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1

Price

Target

Organon & Co. (OGN) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Organon & Co. (OGN) share price will touch around $9 in next 12-months.

Currently 14 wall-street analysts regularly analyze the financials of Organon & Co. on a frequent basis to provide recommendations along with target share price. 14 analysts offering 12-month price forecasts for Organon & Co. (OGN) have a share price target of $9. This median of share price forecast represents a 49.01% upside from the latest price of $6.04 as on 22.03.26.

Organon & Co. (OGN) Share Price Forecast

Home

US Stocks

Organon & Co. (OGN)

Organon & Co. Stock Forecast

Organon & Co. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Organon & Co. (OGN): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Organon & Co.'s share price and its median forecast price. As on 22.03.26, the difference is -18.78%

Organon & Co. Forecast and Target Price

Organon & Co. (OGN) Share Price Forecast

Organon & Co. (OGN) Price vs Consensus Price Target

Organon & Co. (OGN) Share Price Forecast v/s Share Price Today

Organon & Co. (OGN): Difference between Current Price & Median Forecasted Price

Organon & Co. (OGN) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price